Clinical trials: Gut Motility
Food Selection
Pilot Study Using a Wireless Motility Capsule
Research suggests dietary fiber may decrease transit time through the gastrointestinal tract. Research studies traditionally use radio-opaque markers to determine gastric emptying, colonic transit, and whole gut transit time.
- Trial name
- NCT01102894
- Testing
- SmartPill
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Gastroparesis
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
This study is a randomized, double-blind, placebo controlled trial designed to confirm the symptomatic effects of camicinal treatment vs. placebo, on gastroparesis symptoms in type 1 and 2 diabetic subjects with gastroparesis.
- Trial name
- NCT02210000
- Testing
- Camicinal
- Where
- 34 sites in United States
- Volunteers
- 114 people
- Sponsor
- GlaxoSmithKline
Osteoporosis, Achlorhydria
Does Omeprazole Decrease Intestinal Calcium Absorption?
The purpose of this study is to measure the effect of omeprazole on intestinal calcium absorption in postmenopausal women.
- Conditions
- Osteoporosis, Achlorhydria, GERD, Hip Fracture
- Trial name
- NCT00582972
- Testing
- Omeprazole
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Effects of 2 Mu-opiates on Gastrointestinal Transit
Comparison of the Effects of Tapentadol and Oxycodone on Gastrointestinal and Colonic Transit in Humans
Tapentadol is FDA approved for the treatment of moderate to severe acute pain. Due to the dual mechanism of action as an opioid agonist and norepinephrine reuptake inhibitor, there is potential for off label use in chronic pain.
- Trial name
- tap-oxy (NCT01500317)
- Testing
- Tapentadol, Oxycodone
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Gastroparesis
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
GSK962040 is a novel small molecule motilin agonist. The Phase I studies (MOT107043 and MOT109681) demonstrated that single doses of GSK962040 up to 150 mg and repeat dosing of up to 125 mg/day for 14 days were well tolerated…
- Trial name
- NCT01262898
- Testing
- GSK962040 (5 mg tablet), GSK962040 (25 mg tablet), GSK962040 (125 mg tablet)
- Where
- 22 sites in United States, Australia and 4 more
- Volunteers
- 79 people
- Sponsor
- GlaxoSmithKline
Neurogenic Bowel Dysfunction
Stimulation for Colonic Motility
The investigators are testing the effect of electrical stimulation of the rectum on colonic motility. Most individuals with spinal cord injury develop neurogenic bowel dysfunction, which includes slowed colonic motility, which…
- Trial name
- NCT02641483
- Testing
- Electrical Rectal Stimulation
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- VA Office of Research and Development
Gastroparesis
Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE Study
This is a multi-center, parallel group, placebo-controlled and active-compared, randomized study to assess the ability of GSK962040 to enhance the delivery of enteral feed to critically ill subjects that are predisposed to…
- Trial name
- NCT01934192
- Testing
- GSK962040 50 mg, Metoclopramide 10 mg
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 91 people
- Sponsor
- GlaxoSmithKline
Irritable Bowel Syndrome, Constipation
Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syndrome (IBS) With Constipation
Irritable bowel syndrome (IBS) is a common disorder which presents with abdominal pain or discomfort in association with altered bowel habit.
- Trial name
- NCT01162863
- Testing
- Lubiprostone, Smartpill wireless motility capsule
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Michigan
Gastroesophageal Reflux Disease, Functional Bowel Disorders
Temple Registry for the Investigation of African American Gastrointestinal Disease Epidemiology
DESCRIPTION: Minimal data exists on the prevalence of gastroesophageal reflux disease in minority populations. Specific objectives of this K24 research project are to: (1) Provide an estimate of the prevalence of gastroesophageal…
- Trial name
- TRIAGE (NCT01262755)
- Testing
- Structured Interview
- Where
- United States
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Temple University
Irritable Bowel Syndrome
Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor Functions in Patients With Irritable Bowel Syndrome (IBS)
Irritable bowel syndrome (IBS) affects about 15% of the U.S. population. There are still no effective and safe medications approved for the treatment of abdominal pain associated with bowel symptoms in IBS.
- Trial name
- NCT01253408
- Testing
- Dronabinol
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Mayo Clinic
Gastroschisis
Probiotics in Infants With Gastroschisis
Infants born with gastroschisis usually require surgery shortly after birth. After surgery the intestine is often unable to digest human milk or formula for weeks or months.
- Trial name
- NCT01316510
- Testing
- Bifidobacteria infantis
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of California, Davis
Feeding; Difficult, Newborn, Growth Failure
Prophylactic Probiotics to Extremely Low Birth Weight Prematures
Mortality and incidence of severe complications is still high among extremely premature infants. Common causes of severe complications in this population are poor nutrition, necrotizing enterocolitis, and severe infections.
- Conditions
- Feeding; Difficult, Newborn, Growth Failure, Necrotizing Enterocolitis, Sepsis
- Trial name
- PROPEL (NCT01603368)
- Testing
- Lactobacillus reuteri
- Where
- 2 sites in Sweden
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Ostergotland County Council, Sweden
Gastroesophageal Reflux Disease, GERD
To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole
Administration of esomeprazole 20 mg to subjects who still had heartburn after receiving rabeprazole 10 mg once daily for at least 4 weeks will result in statistically significant improvement of heartburn after 8-week treatment.
- Conditions
- Gastroesophageal Reflux Disease, GERD, Reflux Esophagitis
- Trial name
- NCT01397084
- Testing
- esomeprazole 20 mg
- Volunteers
- 107 people
- Sponsor
- AstraZeneca
Erosive Esophagitis
Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study
The purpose of this study was to determine the effect of morning versus bedtime administration of omeprazole/sodium bicarbonate (Zegerid) on endoscopic healing for patients with moderate or severe reflux esophagitis.
- Trial name
- NCT00693225
- Testing
- Omeprazole/sodium bicarbonate
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Yvonne Romero
Gastrointestinal Motility Disorder, Intestinal Disease
Lanreotide in the Treatment of Small Bowel Motility Disorders
This is a human research study looking at the effectiveness of Lanreotide (study medication) in treating small bowel motility disorders.
- Trial name
- NCT03012594
- Testing
- Lanreotide
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Northwell Health
Healthy
Using Magnetic Resonance (MR) to Understand the Effect of Erythromycin on Bowel Motility
Magnetic Resonance Imaging (MRI) has proven to be a valuable imaging technique for suspected small bowel disease. This technique depends, in part, on adequate distension of the small bowel.
- Trial name
- NCT01379183
- Testing
- Erythromycin, Magnetic Resonance Imaging, Barium Sulfate Solution
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Intestinal Cancer, Diverticulitis
Using Electrical Bioimpedance Assessments to Estimate Perioperative Total Body Water and Postoperative Fluid Need
Being able to accurately monitor patient bodily fluid levels during and after surgery is very important, as there are a number of complications that can arise if a patient's fluid levels become unbalanced, such as swelling within…
- Conditions
- Intestinal Cancer, Diverticulitis, Pancreatic Cancer, Gastroesophageal Reflux Disease
- Trial name
- NCT02200055
- Testing
- Bodystat Quadscan 4000
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- United States Naval Medical Center, Portsmouth
Irritable Bowel Syndrome
Effect of a Cannabinoid Agonist on Colonic Sensory Functions in Patients With Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) affects about 15% of the U.S. population. There are still no effective and safe medications approved for the treatment of abdominal pain associated with bowel symptoms in IBS.
- Trial name
- NCT01786109
- Testing
- Dronabinol
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Michael Camilleri
Chronic Idiopathic Constipation
Lubiprostone Effect on Gastrointestinal Tract Transit Times Measured by Smartpill in Patients With Chronic Constipation
The purpose of this study is to determine if lubiprostone may change the rate of movement of food and activities in the stomach and intestines in subjects whose gastrointestinal (GI) tract is slower due to constipation.
- Trial name
- NCT01469819
- Testing
- Lubiprostone
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Texas Tech University Health Sciences Center, El Paso
Intestinal Abnormalities
Diagnosis of Intestinal Motility by Image Analysis Using Capsule Endoscopy
Conventional intestinal manometry is the current gold standard for the evaluation of intestinal motility, and identifies patterns of intestinal dysmotility.
- Trial name
- NCT01085513
- Testing
- PillCam SB2
- Where
- 6 sites in United States, Belgium and 3 more
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- Medtronic - MITG